Roughly half of surveyed pulmonologists treating patients with IPF have concerns about tolerability and side effects with currently available options, according to Spherix Global Insights, GmbH
Nov 30, 2015 – Zug, Switzerland – Feedback gathered from the recently released Market Dynamix: Idiopathic Pulmonary Fibrosis (IPF) reveals that IPF remains a challenging disease to treat, especially as most diagnosed patients are in the later stages of this progressive disease. Furthermore, there is a concern that following FDA approval for both Esbriet and Ofev, future treatments will have an even higher threshold of efficacy to reach, potentially slowing down the arrival of new molecules.
Multiple companies including Afferent, Biogen, FibroGen, Gilead and MediciNova are currently developing future therapies for the treatment of IPF. However, physicians have very little awareness about the future therapy options, and what potential benefits they may bring. Beyond specialist treatment centers, physicians continue to debate the benefits of using older steroid-based therapies, and outside of established guidelines, patients themselves continue to investigate other treatment options, including stem cell innovations. Over 80% of physicians included in this study state that the primary goal for treatment remains to slow the progression of this disease, a goal that continues to be aspirational.
Market Dynamix: Idiopathic Pulmonary Fibrosis is based on responses to an online survey of 100 IPF-treating pulmonologists and 15 in-depth qualitative interviews with international thought leaders conducted during the fourth quarter of 2015. Further insight into the IPF market can be gleaned from an upcoming Spherix deliverable: RealWorld Dynamix: Idiopathic Pulmonary Fibrosis which is based on in-depth analysis of approximately 800 IPF patient records.
About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company headquartered in Zug, Switzerland with US offices in Cambridge, MA. We specialize in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.